Metastatic Renal Cell Carcinoma Presenting as a Bleeding Gastric Polyp

REFERENCES

1. 1.↵
   1. Xu J,
   2. Latif S,
   3. Wei S

   . Metastatic renal cell carcinoma presenting as gastric polyps: a case report and review of the literature. Int J Surg Case Rep. 2012;3(12):601-604. doi: 10.1016/j.ijscr.2012.08.009.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Sadler GJ,
   2. Anderson MR,
   3. Moss MS,
   4. Wilson PG

   . Metastases from renal cell carcinoma presenting as gastrointestinal bleeding: two case reports and a review of the literature. BMC Gastroenterol. 2007 Jan 31;7:4. doi: 10.1186/1471-230X-7-4.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Weigt J,
   2. Malfertheiner P

   . Metastatic disease in the stomach. Gastrointest Tumors. 2015 Sep;2(2):61-64. doi: 10.1159/000431304.

   OpenUrlCrossRef
4. 4.↵
   1. Dufies M,
   2. Giuliano S,
   3. Ambrosetti D,
   4. et al.

   Sunitinib stimulates expression of VEGFC by tumor cells and promotes lymphangiogenesis in clear cell renal cell carcinomas. Cancer Res. 2017 Mar 1;77(5):1212-1226. doi: 10.1158/0008-5472.CAN-16-3088.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Namikawa T,
   2. Hanazaki K

   . Clinicopathological features and treatment outcomes of metastatic tumors in the stomach. Surg Today. 2014 Aug;44(8):1392-1399. doi: 10.1007/s00595-013-0671-9.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Kim GH,
   2. Ahn JY,
   3. Jung HY,
   4. et al.

   Clinical and endoscopic features of metastatic tumors in the stomach. Gut Liver. 2015 Sep 23;9(5):615-622. doi: 10.5009/gnl14032.

   OpenUrlCrossRef
7. 7.↵
   1. Shaaban H,
   2. Modi Y,
   3. Modi T,
   4. Guron G

   . Diffuse gastroduodenal metastasis from cutaneous malignant melanoma presenting as amelanotic “volcano-like” ulcers. J Gastrointest Cancer. 2014 Mar;45(1):116-117. doi: 10.1007/s12029-013-9515-5.

   OpenUrlCrossRef
8. 8.↵
   1. Oda I,
   2. Kondo H,
   3. Yamao T,
   4. et al.

   Metastatic tumors to the stomach: analysis of 54 patients diagnosed at endoscopy and 347 autopsy cases. Endoscopy. 2001 Jun;33(6):507-510.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Onorati M,
   2. Petracco G,
   3. Uboldi P,
   4. et al.

   A solitary polypoid gastric metastasis 20 years after renal cell carcinoma: an event to be considered, and a brief review of the literature. Pathologica. 2013 Aug;105(4):132-136.

   OpenUrl
10. 10.↵
    1. Ciccarese C,
    2. Brunelli M,
    3. Montironi R,
    4. et al.

    The prospect of precision therapy for renal cell carcinoma. Cancer Treat Rev. 2016 Sep;49:37-44. doi: 10.1016/j.ctrv.2016.07.003.

    OpenUrlCrossRef
11. 11.↵
    1. Go H,
    2. Kang MJ,
    3. Kim PJ,
    4. et al.

    Development of response classifier for vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitor (TKI) in metastatic renal cell carcinoma. Pathol Oncol Res. 2017 Sep 29. doi: 10.1007/s12253-017-0323-2. [Epub ahead of print].

    OpenUrlCrossRef
12. 12.↵
    1. Dornbusch J,
    2. Walter M,
    3. Gottschalk A,
    4. et al.

    Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients. J Cancer Res Clin Oncol. 2016 Jun;142(6):1171-1182. doi: 10.1007/s00432-016-2137-0.

    OpenUrlCrossRef
13. 13.↵
    1. Kontovinis LF,
    2. Papazisis KT,
    3. Touplikioti P,
    4. Andreadis C,
    5. Mouratidou D,
    6. Kortsaris AH

    . Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer. 2009 Mar 12;9:82. doi: 10.1186/1471-2407-9-82.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Négrier S,
    2. Raymond E

    . Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs. 2012 Aug;30(4):1791-1801. doi: 10.1007/s10637-011-9677-6.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Zucca LE,
    2. Morini Matushita MA,
    3. da Silva Oliveira RJ,
    4. et al.

    Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib. Urol Oncol. 2018 Jan;36(1):11.e13-11.e21. doi: 10.1016/j.urolonc.2017.09.003.

    OpenUrlCrossRef
16. 16.↵
    1. Miao C,
    2. Cao J,
    3. Wang Y,
    4. Liu B,
    5. Wang Z

    . Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis. Oncotarget. 2017 Aug 4;8(40):68854-68862. doi: 10.18632/oncotarget.19924.

    OpenUrlCrossRef
17. 17.↵
    1. Merseburger AS,
    2. Simon A,
    3. Waalkes S,
    4. Kuczyk MA

    . Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther. 2009 Oct;9(10):1429-1434. doi: 10.1586/era.09.96.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Kapoor A

    . First-line treatment options in metastatic renal cell cancer. Can Urol Assoc J. 2016 Nov-Dec;10(11-12Suppl7):S236-S238. doi: 10.5489/cuaj.4307.

    OpenUrlCrossRef